Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met

Kintor Pharma Announces The Primary Endpoint Of Phase Ii Clinical Study For Kx 826's Treatment Of Androgenetic Alopecia Was Met

Facebook Comments

Leave a Reply

CommentLuv badge